Go to Contents Go to Navigation

Moon pledges full support in swift phase 3 clinical trial for country's first home-developed vaccine: spokesperson

All News 15:09 August 10, 2021

SEOUL, Aug. 10 (Yonhap) -- President Moon Jae-in on Tuesday promised to provide full governmental support to swiftly and sufficiently move forward the phase three clinical trial of the country's first home-developed vaccine candidate.

The government announced earlier in the day that South Korean drugmaker SK Bioscience Co. has won an approval to conduct the phase three clinical trial of GBP510.

In response to the news, Moon said "the government will provide full-fledged support to ensure that the domestic clinical trial can be conducted swiftly and sufficiently," Cheong Wa Dae spokesperson Park Kyung-mee said.

President Moon Jae-in speaks during a meeting with his senior secretaries at the presidential office, Cheong Wa Dae, in Seoul on Aug. 9, 2021. (Yonhap)

The president also expressed hope for successful commercialization of South Korea's first home-developed coronavirus vaccine product, Park added.

Throughout the course of the pandemic, Moon has consistently underscored the need for South Korea to have its own proprietary vaccine product, as Seoul has remained reliant entirely on foreign drug makers for its coronavirus vaccination.

On Monday, Moon stated that the country will "speed up developments of domestic vaccines as to not be swayed by overseas companies" and also aggressively push forward with its strategy to become a global vaccine.

The president also said, in a vaccine hub strategy meeting last week, that South Korea plans to invest 2.2 trillion won (US$1.92 billion) in the next five years to become the world's fifth-largest vaccine-producing nation.

This photo from Jan. 20, 2021, shows SK Bioscience Co.'s vaccine manufacturing plant in Andong, 270 kilometers southeast of Seoul. (PHOTO NOT FOR SALE) (Yonhap)


Send Feedback
How can we improve?
Thanks for your feedback!